Buy Rating Affirmed for PMV Pharmaceuticals Amid Stable Financials and Strategic Growth Potential
I'm PortAI, I can summarize articles.
H.C. Wainwright analyst Robert Burns has reaffirmed a Buy rating for PMV Pharmaceuticals, citing stable financials and strategic growth potential. The company's Q3 2025 results showed a net loss per share in line with expectations, supported by a substantial cash reserve projected to last until Q1 2027. PMV's valuation, estimated at $263 million, factors in a 10% approval probability for rezatapopt in solid tumors. Risks include clinical setbacks. Oppenheimer also maintains a Buy rating with a $6.00 price target.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments